* Tonix Pharmaceuticals Holding Corp is expected to show a rise in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2024
* The Chatham New Jersey-based company is expected to report revenue of $3.8 million, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Tonix Pharmaceuticals Holding Corp is for a loss of 39 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 23.3% in the last three months.
* Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $2.25, above its last closing price of $0.17.
This summary was machine generated May 3 at 13:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments